UNAIDS. Miles to Go—Closing Gaps, Breaking Barriers, Righting Injustices, 2018. Available at: www.unaids.org/sites/default/files/media_asset/miles-to-go_en.pdf (Last accessed July24, 2018).
2.
FonnerVA, DalglishSL, KennedyCE, et al.Effectiveness and safety of oral HIV pre-exposure prophylaxis (PrEP) for all populations: A systematic review and meta-analysis. AIDS, 2016; 30:1973–1983.
3.
GulickRM. Editorial: New HIV drugs: 2018 and beyond. Curr Opin HIV AIDS, 2018; 13:291–293.
4.
BuchbinderSP, LiuAY. CROI 2018: Epidemic trends and advances in HIV prevention. Topics Antiviral Med, 2018; 26:1–16.
5.
BazziAR, LeechAA, BiancarelliDL, SullivanM, DrainoniM-L. Experiences using pre-exposure prophylaxis for safer conception among HIV serodiscordant heterosexual couples in the United States. AIDS Patient Care STDs, 2017; 31:348–355.
6.
GulickRM, WilkinTJ, ChenYQ, et al.Safety and tolerability of maraviroc-containing regimens to prevent HIV infection in women. A phase 2 randomized trial. Ann Intern Med, 2017; 167:384–393.
7.
RyomL, MocroftA, KirkO, et al.Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. AIDS, 2017; 31:1261–1270.
8.
MorlatP, VivotA, VandenhendeM-A, et al.Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitane cohort, France, 2004–2012. PLoS One, 2013; 8:e66223.
9.
VolkJE, MarcusJL, PhengrasamyT, et al.No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis, 2015; 61:1601–1603.
10.
MarcusJL, LevineK, GrassoC, et al.HIV preexposure prophylaxis as a gateway to primary care. Am J Public Health, 2018; 108:1418–1420.
11.
PhilbinMM, ParkerCM, ParkerRG, WilsonPA, GarciaJ, HirschJS. The promise of pre-exposure prophylaxis for black men who have sex with men: An ecological approach to attitudes, beliefs, and barriers. AIDS Patient Care STDs, 2016; 30:282–290.
12.
WilsonE, ChenY-H, PomartA, ArayasirikulS. Awareness, interest, and HIV pre-exposure prophylaxis candidacy among young transwomen. AIDS Patient Care STDs, 2016; 30:147–150.
13.
KrakowerDS, WareNC, MaloneyKM, WilsonIB, WongJB, MayerKH. Differing experiences with pre-exposure prophylaxis in Boston among lesbian, gay, bisexual, and transgender specialists and generalists in primary care: Implications for scale-up. AIDS Patient Care STDs, 2017; 31:297–304.
14.
MarksSJ, MerchantRC, ClarkMA, et al.Potential healthcare insurance and provider barriers to pre-exposure prophylaxis utilization among young men who have sex with men. AIDS Patient Care STDs, 2017; 31:470–478.
15.
ZahnB.Barriers remain in HIV-preventative pill use. Greenwich Time, August 6, 2018, p. A5.
16.
HoltM, LeaT, MaoL, et al.Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: Results of repeated behavioural surveillance in 2013–17. Lancet HIV, 2018; 5:e448–e456.
17.
GraceD, JollimoreJ, MacPhersonP, StrangMJP, TanDHS. The pre-exposure prophylaxis-stigma paradox: Leaning from Canada's first wave of PrEP users. AIDS Patient Care STDs, 2018; 32:24–30.
18.
NguyenV-K, GreenwaldZR, TrottierH, et al.Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV. AIDS, 2018; 32:523–530.
19.
MarcusJL, VolkJE, SnowdenJM. Concerns about a study on sexually transmitted infections after initiation of HIV preexposure prophylaxis. AIDS, 2018; 32:955–956.
20.
MolinaJ-M, ChatteauI, SpireB, et al.Efficacy, safety, and effect on sexual behavior of on-demand pre-exposure prophylaxis in men who have sex with men: An observational cohort study. Lancet HIV, 2017; 4:e:402–e410.
21.
WongNS, KwanTH, TsangOTY, et al.Pre-exposure prophylaxis (PrEP) for MSM in low HIV incidence places: Should high risk individuals be targeted?. Sci Rep, 2018; 18:11641.
22.
ShoverCL, JavanbakhtM, ShoptawS, BolanR, GorbachP. High discontinuation of pre-exposure prophylaxis within six months of initiation. Conference on Retroviruses and Opportunistic Infections, Boston MA, March 4–7, 2018, Abst. 1009.
23.
MartinM, VanichseniS, SuntharasamaiP, et al.Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: An observational, open-label extension of the Bangkok Tenofovir Study. Lancet HIV, 2017; 4:e59–e66.
24.
VolkJE, NguyenDP, HareCB, MarcusJL. HIV infection and drug resistance with unsupervised use of HIV pre-exposure prophylaxis. AIDS Res Human Retrov, 2018; 34:329–330.
